Addex provides update on adx71149 phase 2 epilepsy study

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, april 29, 2024 - addex therapeutics (six and nasdaq: adxn), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a phase 2 epilepsy study evaluating adjunctive adx71149 (jnj-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
ADXN Ratings Summary
ADXN Quant Ranking